HK inno.N begins selling reflux treatment in Peru

Home > Business > Industry

print dictionary print

HK inno.N begins selling reflux treatment in Peru

  • 기자 사진
  • SHIN HA-NEE
HK inno.N hosted a symposium in Peru in August ahead of the market release of its Ki-CAB tablet, a gastroesophageal reflux disease treatment, in October. [HK INNO.N]

HK inno.N hosted a symposium in Peru in August ahead of the market release of its Ki-CAB tablet, a gastroesophageal reflux disease treatment, in October. [HK INNO.N]

 
HK inno.N has begun selling its K-CAB tablet, a gastroesophageal reflux disease treatment, in Peru, the pharmaceutical company said Monday.
 
The drug was made available in the market starting Oct. 12, under the brand Ki-CAB. The local sales of the drug in Peru as well as 16 other Latin American countries are being handled by Laboratorios Carnot. 
 
Peru is K-CAB’s second destination for market release in the region following Mexico, where HK inno.N began selling the drug in May, and seventh outside Korea.
 
K-CAB is currently available in China, Mongolia, Philippines, Mexico, Indonesia, Singapore and Peru, through technology or product exports.
 
HK inno.N has signed technology or product export contracts for K-CAB with a total of 35 countries overseas, such as the United States, China and 18 Latin American nations including Brazil.
 

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)